Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA studyIdanna Innocenti, Luca Laurenti, Gianluigi Reda et al.|Haematologica|2022Cited by 20
Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLLLydia Scarfò, Paolo Ghia, Silvia Heltai et al.|Blood|2022Cited by 10
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor modelStefano Molica, Francesca Romana Mauro, Anna Maria Frustaci et al.|American Journal of Hematology|2022Cited by 10
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Francesca Romana Mauro, Candida Vitale et al.|Leukemia|2025Cited by 5
Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK PathwayLodovico Terzi di Bergamo, Davide Rossi, Gabriela Forestieri et al.|Blood|2024Cited by 4